**Name of Journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 31866**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**Association of obesity and** ***Helicobacter pylori* infection: a retrospective study**

Xu MY *et al*. Association of obesity and *H. pylori*

Mei-Yan Xu, Lan Liu, Bao-Shi Yuan, Jian Yin, Qing-Bin Lu

**Mei-Yan Xu, Jian Yin,** Department of Nutrition, Aerospace Center Hospital, Beijing 100049, China

**Lan Liu, Bao-Shi Yuan,** Department of Health Management, Aerospace Center Hospital, Beijing 100049, China

**Qing-Bin Lu,** School of Public Health, Peking University, Beijing 100191, China

**Author contributions:** Xu MY and Liu L contributed equally to this work; Lu QB, Xu MY and Liu L designed the study, analyzed the data and wrote the paper; Liu L, Yin J and Yuan BS collected the data; Yin J and Yuan BS revised the paper; all authors have read and approved the final version to be published.

**Supported by** the State Key Laboratory of Pathogen and Biosecurity (Academy of Military Medical Science), No. SKLPBS1442; and the Youth Talent Support Program by the School of Public Health, Peking University.

**Institutional review board statement:** This study was reviewed and approved by the Research Ethics Committee of Aerospace Center Hospital.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available in this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Qing-Bin Lu, MD,** School of Public Health, Peking University, No. 38 Xue-Yuan Road, Haidian District, Beijing 100191, China. qingbinlu@bjmu.edu.cn

**Telephone:** +86-10-82805327

**Fax:** +86-10-82805327

**Received:** December 12, 2016

**Peer-review started:** December 14, 2016

**First decision:** December 29, 2016

**Revised:** January 17, 2017

**Accepted:** March 15, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

to explore the association between *Helicobacter pylori* (*H. pylori*) infection and obesity/weight gain in the population in China.

***METHODS***

Our primary outcome was the change in body mass index (BMI). The generalized linear models were used to explore the association between *H. pylori* infection and the change value of BMI, and the logistic regression models were used to explore the association between *H. pylori* infection and obesity.

***RESULTS***

A total of 3039 subjects were recruited and analyzed. 12.8% of subjects were obese. The prevalence of *H. pylori* infection was 53.9% (1639/3039) overall and 54.6% (212/388) in the obese subjects. The change value of BMI in the *H. pylori* (+) group was not significantly higher than that in the *H. pylori* (-) group after adjustment for the potential confounding factors (RR = 0.988, 95%CI: 0.924-1.057, *P* = 0.729). The prevalence of obesity decreased 1.1% in the *H. pylori* (+) group and 0.5% in the *H. pylori* (-) group. The RR of *H. pylori* infection for obesity was 0.831 (95%CI: 0.577-1.197; *P* = 0.321) after the adjustment.

***CONCLUSION***

*H. pylori* infection was not associated with overweight/obesity observed from the retrospective study in this Chinese population.

**Key words:** Obesity; *Helicobacter pylori*; retrospective study; China

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The association between *Helicobacter pylori* (*H. pylori*) and obesity/weight gain is still unclear and controversial. We performed this retrospective study with a large sample size to explore the association between *H. pylori* infection and obesity/weight gain in Chinese people. The change in body mass index and the prevalence of obesity over two years in the *H. pylori* (+) group was not significantly higher than that in the *H. pylori* (-) group. We concluded that *H. pylori* infection was not associated with overweight/obesity observed from this study of Chinese people.

Xu MY, Liu L, Yuan BS, Yin J, Lu QB. Association of obesity and *Helicobacter pylori* infection: a retrospective study. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

Obesity is defined as excessive fat accumulation that may impair health. The World Health Organization estimated that over 600 million people in the world were obese in the year 2014. The worldwide prevalence of obesity more than doubled between 1980 and 2014. Obesity is associated with infectious diseases, such that certain infections may trigger an increase in adiposity, such as human adenovirus 36, H1N1/influenza, Human Immunodeficiency Virus, and *Helicobacter pylori* (*H. pylori*)[[1](#_ENREF_1)].

*H. pylori* is one of the most common human infections, and it is estimated that more than half of the world’s population is infected[[2](#_ENREF_2)]. *H. pylori* has been linked to gastritis, gastric ulcers and gastric cancer[[3-5](#_ENREF_3)]. The association between *H. pylori* and obesity/weight gain remains unclear and controversial.

The prevalence of *H. pylori* infection was reported to be from 8.7% to 85.5%[[6](#_ENREF_6)]. A lower prevalence of *H. pylori* infection was found in obese patients than in the general population[[6](#_ENREF_6)]. Other studies have reported a higher *H. pylori* prevalence in obese patients[[7](#_ENREF_7),[8](#_ENREF_8)]. The systematic review by Dhurandhar *et al*[[1](#_ENREF_1)] reported an increase in weight gain or an increase in the biomarkers associated with weight gain after *H. pylori* eradication, and most cross-sectional studies found evidence of a higher prevalence of *H. pylori* infection in obese individuals or metabolic impairment in the presence of the infection.

One study indicated an inverse relationship between morbid obesity and *H. pylori* seropositivity, leading to the hypothesis that the absence of *H. pylori* infection during childhood may enhance the risk of the development of morbid obesity[[9](#_ENREF_9)]. The significant increase in body mass index (BMI) observed after eradication of *H. pylori* highlights a possible inverse correlation between *H. pylori* infection and obesity[[10](#_ENREF_10),[11](#_ENREF_11)]. Several studies did not find any influence of bacterial eradication on body weight[[12](#_ENREF_12),[13](#_ENREF_13)]. In a large randomized controlled study, Lane and colleagues found a significant increase in body mass following eradication of *H. pylori* in a European population[[10](#_ENREF_10)]. A meta-analysis of 18 observational studies including 10,000 subjects found a higher body mass index among *H. pylori*-positive subjects compared with *H. pylori*-negative subjects[[14](#_ENREF_14)]. A cross-sectional study showed that *H. pylori* infection was significantly and positively associated with overweight/obesity in a Chinese population[[15](#_ENREF_15)]. Reports from different areas and countries were not consistent with each other, and most were cross-sectional studies. It is therefore necessary to perform this study to further explore the true association between *H. pylori* and obesity.

Therefore, we performed this retrospective study to explore the association between *H. pylori* infection and obesity/weight gain in the population of China.

**MATERIALS AND METHODS**

***Study design and participants***

This observational and retrospective study was performed in the Aerospace Center Hospital in Beijing, China. We retrieved the data of all the subjects in a certain unit in 2012 from the registration system. The subjects without detection of *H. pylori* infection or data regarding height/weight were excluded. We then searched the data regarding height and weight of the same patient population in 2013.

We performed a chart review of all recruited subjects to collect the information regarding demographic characteristics, underlying diseases (diabetes, hypertension and coronary heart disease), and laboratory test results, including low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides (TG), total cholesterol (TC) and fasting blood-glucose (FBG). The height and weight of all the subjects were measured at baseline and at 1-year follow up. The *H. pylori* status was estimated by enzyme linked immunosorbent assay (ELISA) for anti-*H. pylori* IgG and IgM. This study was performed with the approval of the Ethical Committees of the hospital. The methods were carried out in accordance with the approved guidelines. At recruitment, written informed consent was obtained from the subjects.

***Outcomes***

Our primary outcome was the change in BMI. The secondary outcome was the onset of obesity.

***Statistical analysis***

BMI was calculated by the weight (kg) divided by the square of the height (m). Obesity was defined as BMI equal to or greater than 28 kg/m2,and overweight was defined as BMI equal to or greater than 24 kg/m2 and less than 28 kg/m2, as recommended by the Working Group on Obesity in China[[16](#_ENREF_16)]. Descriptive statistics were performed, with continuous variables summarized as median and range and categorical variables summarized as frequencies and proportions. The statistical significance between the various groups was tested using the *χ2*-test or Fisher’s exact test for categorical variables and the independent t test for continuous variables. Generalized linear models were used to explore the association between *H. pylori* infection and the change in BMI. Logistic regression models were used to explore the association between *H. pylori* infection and obesity. The variables of age, sex, marital status, underlying diseases, LDL, HDL, TGs, TC and FBG were adjusted in the above models. Risk ratios (RRs) and their 95% confidence intervals (CIs) were estimated. A two-sided *P* < 0.05 was considered to be statistically significant. All analyses were performed using Stata 12.0 (Stata Corp LP, College Station, TX, United States).

**RESULTS**

***Subjects***

A total of 16462 subjects participated in the health examination in the hospital. The diagram of the subjects included in the study is shown in Figure 1. Among all the subjects, 13390 were excluded due to the absence of *H. pylori* detection results or BMI data, and 33 (1.1%) subjects were lost to follow-up. Finally, 3039 subjects were recruited and analyzed.

The characteristics of the subjects in this study are shown in Table 1. The mean (SD) age of all the subjects was 49 (19) years old, and 248 (8.2%) were female. A total of 770 (22.5%) subjects had underlying diseases, including 21.1% with hypertension, 6.8% with diabetes and 5.8% with coronary heart disease. The mean (standard deviation) BMI was 24.5 (3.3) kg/m2. Most (44.2%) of the subjects were of normal weight, 41.0% were overweight and 12.8% were obese.

***H. pylori distribution***

The overall prevalence of *H. pylori* infection was 53.9% (1639/3039), and the prevalence was 54.6% (212/388) in the obese subjects. Higher rates of seroprevalence were demonstrated in the subjects who were older, married, had underlying diseases, hypertension or higher FBG (all *P* < 0.05), as shown in Table 1. No significant associations were found between *H. pylori* and BMI/obesity at the baseline survey (*P* > 0.05).

***Association between H. pylori and BMI***

Observed from all the subjects, the BMI decreased from the baseline to the 1-year follow up in both the *H. pylori* (+) group (*r* = -0.169, Figure 2A)and the *H. pylori* (-) group (*r* = -0.189, Figure 2B). However, the change in value of BMI in the *H. pylori* (+) group was not significantly higher than that in the *H. pylori* (-) group after adjusting for age, sex, marriage, underlying diseases, LDL, HDL, TGs, TC and FBG (RR = 0.988, 95%CI: 0.924-1.057, *P* = 0.729), as shown in Table 2. BMI significantly decreased in the overweight and obese subjects at the 1-year follow up, while it was non-significantly increased in the underweight and normal weight subjects (Table 2 and Figure 3). Differences were not found between *H. pylori* infectionand BMI change in different BMI groups (all P>0.05).

***Association between H. pylori and obesity***

The prevalence of obesity decreased 1.1% in the *H. pylori* (+) group and 0.5% in the *H. pylori* (-) group (Table 3). The RR of *H. pylori* infection for obesity was 0.831 (95%CI: 0.577-1.197; *P* = 0.321) after the adjustment. In the obese subjects, the decreased prevalence of obesity was 19.9% and 19.1% in the *H. pylori* (+) and the *H. pylori* (-) group, respectively. Compared with the *H. pylori* (-) group, the subjects in the *H. pylori* (+) group lost weight more easily (RR = 0.931; 95%CI: 0.574-1.585; *P* = 0.972). In the non-obese subjects, the prevalence of obesity in the *H. pylori* (+) group was lower than that in the *H. pylori* (-) group (RR = 0.673; 95%CI: 0.382-1.186; *P* = 0.170).

**DISCUSSION**

We evaluated the relationship between *H. pylori* infection and obesity/weight gain in the population using a retrospective study. No significant differences were found during the analysis. Despite the lack of significant differences, we found a trend toward weight loss in conjunction with *H. pylori* infection.

The prevalence of *H. pylori* in the general population was 53.6%, which was similar to other Asian countries (Japan and Taiwan), lower than in most European and South American countries and higher than those in North America and Australia[[6](#_ENREF_6)]. These discrepancies might be related to both small sample size and variability in diagnostic testing. Different methods are used to diagnose *H. pylori* infection. Serology had a low diagnostic accuracy of only 80%-84%, which is only useful to exclude *H. pylori*,while the urea breath test (UBT) performed better with a sensitivity of 88%-95% and a specificity of 95%-100%[[6](#_ENREF_6)]. Therefore, in order to give a correct diagnosis, positive serology and UBT should be performed together before treatment.

Some studies reported that eradication of *H. pylori* was associated with metabolic disturbances including weight gain[[17-19](#_ENREF_17)]. Some studies have given an explanation about the effect of *H. pylori* eradication; one was that *H. pylori* eradication increases the gastric secretion of ghrelin, which leads to increased appetite and weight gain[[20](#_ENREF_20),[21](#_ENREF_21)]. The precise effect of gastric secretion of ghrelin on circulating ghrelin levels is not straightforward. Another explanation was that the eradication of *H. pylori* decreases gastric leptin expres­sion, and this decrease was accompanied by an increase in BMI[[22](#_ENREF_22)]. The effects of *H. pylori* on ghrelin and leptin strongly suggest that the bacterium ‘protects’ against obesity. The decreasing incidence of this infection may be contributing to an increase in appetite and food intake. Unfortunately, these mechanisms were not invariably confirmed. Epidemiological studies have failed to show any association between *H. pylori* infection and BMI, with a meta-analysis of 18 observational studies that reported a slightly higher BMI in *H. pylori* positive patients[[14](#_ENREF_14)]. In our study, the *H. pylori* infection appeared to be a protective factor for obesity. The subjects with *H. pylori* (+) had decreased BMI more than those with *H. pylori* (-), although the differences were not significant, which was opposite to the result of the cross-sectional study by Zhang *et al*[[15](#_ENREF_15)]. This contrary finding may be attributed to different populations being analyzed and/or the different methods used to make the diagnosis. Another reason may be the increased in intestinal permeability and the role of gut microbiota to induce insulin resistance and liver steatosis[[23](#_ENREF_23),[24](#_ENREF_24)]. Based on that, we think that *H. pylori* infection may be limited in order to lose weight, and the eradication of *H. pylori* may be limited in order to gain weight. The primary cause of weight gain is changes in lifestyle. The intake of fat and carbohydrates increases, while physical activity clearly decreases.*H. pylori* infection was associated with decreased gastric expression of leptin and ghrelin and correlated negatively with patient energy intake and body mass index[[25](#_ENREF_25)]. It can be postulated that *H. pylori* infection due to effects on leptin and ghrelin protects against the intake of large amount of calories in these patients.

Our study had several important limitations. The primary limitation is that our study had a short-term follow up of only one-year, and then we could not achieve a significant outcome from the portion of the subjects who attended follow-up. Another limitation is that we did not consider the effect of the treatment on the *H. pylori* infection during the follow up time, which may influence the association between *H. pylori* infection and weight gain. We did not analyze the effect of insulin resistance on the association between *H. pylori* and obesity. Serological testing for the presence of anti-*H. pylori* IgG and IgM does not indicate a current infection and only shows exposure to these bacteria, which may have biased the detection of *H. pylori* infection. The last limitation is that the ratio of males to females was high due to the characteristics of the unit. These above limitations may have biased certain outcomes of the results.

In conclusion, *H. pylori* infection was not associated with overweight/obesity observed in the retrospective study in this Chinese population.

**ACKNOWLEDGMENTS**

We would like to thank Lai-Lai Yan from the School of Public Health, Peking University for his support and assistance in this study.

**COMMENTS**

***Background***

The World Health Organization estimated that over 600 million people were obese in the world in year 2014. Obesity is interlinked with infectious diseases, such that certain infections may trigger an increase in adiposity, such as *Helicobacter pylori* (*H. pylori*). *H. pylori* has been linked with gastritis, gastric ulcers and gastric cancer. The association between *H. pylori* and obesity/weight gain is still unclear and controversial. Reports from different areas and countries are not consistent with each other, and most were cross-sectional studies. It was therefore necessary to perform this study to further explore the true association between *H. pylori* and obesity. Therefore, we performed this retrospective study to explore the association between *H. pylori* infection and obesity/weight gain in a population in China.

***Research frontiers***

Some studies reported that the eradication of *H. pylori* was associated with metabolic disturbances including weight gain, but the mechanisms were not invariably confirmed. Epidemiological studies have failed to show any association between *H. pylori* infection and body mass index.

***Innovations and breakthroughs***

No significant differences were found between *H. pylori* infection and obesity/weight gain during the analysis. In spite of this, the authors also found a trend toward weight loss with *H. pylori* infection.

***Applications***

These results provide evidence that *H. pylori* infection may be not associated with obesity or weight gain, which means *H. pylori* infection may be limited in weight loss; that is, eradication of *H. pylori* may be limited in order to gain weight.

***Terminology***

BMI, body mass index, is used to quantify the amount of tissue mass (muscle, fat, and bone) in an individual then categorize that person as underweight, normal weight, overweight, or obese based on that value.

***Peer-review***

This is a well-designed, performed and written retrospective clinical study for the evaluation of the association between *H. pylori* infection and obesity in the population in China.

**REFERENCES**

1 **Dhurandhar NV**, Bailey D, Thomas D. Interaction of obesity and infections. *Obes Rev* 2015; **16**: 1017-1029 [PMID: 26354800 DOI: 10.1111/obr.12320]

2 **Malfertheiner P**, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]

3 **Wotherspoon AC**, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. *Lancet* 1991; **338**: 1175-1176 [PMID: 1682595]

4 **Khatoon J**, Rai RP, Prasad KN. Role of Helicobacter pylori in gastric cancer: Updates. *World J Gastrointest Oncol* 2016; **8**: 147-158 [PMID: 26909129 DOI: 10.4251/wjgo.v8.i2.147]

5 **Chang SS**, Hu HY. Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens. *World J Gastrointest Pharmacol Ther* 2015; **6**: 127-136 [PMID: 26558147 DOI: 10.4292/wjgpt.v6.i4.127]

6 **Carabotti M**, D'Ercole C, Iossa A, Corazziari E, Silecchia G, Severi C. Helicobacter pylori infection in obesity and its clinical outcome after bariatric surgery. *World J Gastroenterol* 2014; **20**: 647-653 [PMID: 24574738 DOI: 10.3748/wjg.v20.i3.647]

7 **Arslan E**, Atilgan H, Yavaşoğlu I. The prevalence of Helicobacter pylori in obese subjects. *Eur J Intern Med* 2009; **20**: 695-697 [PMID: 19818289 DOI: 10.1016/j.ejim.2009.07.013]

8 **Dutta SK**, Arora M, Kireet A, Bashandy H, Gandsas A. Upper gastrointestinal symptoms and associated disorders in morbidly obese patients: a prospective study. *Dig Dis Sci* 2009; **54**: 1243-1246 [PMID: 18975090 DOI: 10.1007/s10620-008-0485-6]

9 **Wu MS**, Lee WJ, Wang HH, Huang SP, Lin JT. A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan. *Arch Intern Med* 2005; **165**: 1552-1555 [PMID: 16009873 DOI: 10.1001/archinte.165.13.1552]

10 **Lane JA**, Murray LJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. *Aliment Pharmacol Ther* 2011; **33**: 922-929 [PMID: 21366634 DOI: 10.1111/j.1365-2036.2011.04610.x]

11 **Yang YJ**, Sheu BS, Yang HB, Lu CC, Chuang CC. Eradication of Helicobacter pylori increases childhood growth and serum acylated ghrelin levels. *World J Gastroenterol* 2012; **18**: 2674-2681 [PMID: 22690077 DOI: 10.3748/wjg.v18.i21.2674]

12 **Jang EJ**, Park SW, Park JS, Park SJ, Hahm KB, Paik SY, Sin MK, Lee ES, Oh SW, Park CY, Baik HW. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. *J Gastroenterol Hepatol* 2008; **23 Suppl 2**: S278-S285 [PMID: 19120912 DOI: 10.1111/j.1440-1746.2008.05415.x]

13 **Kawano S**, Kawahara A, Nakai R, Fu HY, Tsuji S, Tsujii M. Helicobacter pylori infection does not affect serum leptin concentration and body mass index (BMI) in asymptomatic subjects. *J Gastroenterol* 2001; **36**: 579-580 [PMID: 11519840]

14 **Danesh J**, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. *BMJ* 1998; **316**: 1130-1132 [PMID: 9552950]

15 **Zhang Y**, Du T, Chen X, Yu X, Tu L, Zhang C. Association between Helicobacter pylori infection and overweight or obesity in a Chinese population. *J Infect Dev Ctries* 2015; **9**: 945-953 [PMID: 26409735 DOI: 10.3855/jidc.6035]

16 **Zhou BF**; Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. *Biomed Environ Sci* 2002; **15**: 83-96 [PMID: 12046553]

17 **Al-Nozha M**, Al-Khadra A, Arafah MR, Al-Maatouq MA, Khalil MZ, Khan NB, Al-Mazrou YY, Al-Marzouki K, Al-Harthi SS, Abdullah M, Al-Shahid MS, Al-Mobeireek A, Nouh MS. Metabolic syndrome in Saudi Arabia. *Saudi Med J* 2005; **26**: 1918-1925 [PMID: 16380773]

18 **Scharnagl H**, Kist M, Grawitz AB, Koenig W, Wieland H, März W. Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol. *Am J Cardiol* 2004; **93**: 219-220 [PMID: 14715353]

19 **Albaker WI**. Helicobacter pylori infection and its relationship to metabolic syndrome: is it a myth or fact? *Saudi J Gastroenterol* ; **17**: 165-169 [PMID: 21546717 DOI: 10.4103/1319-3767.80377]

20 **Osawa H**, Nakazato M, Date Y, Kita H, Ohnishi H, Ueno H, Shiiya T, Satoh K, Ishino Y, Sugano K. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. *J Clin Endocrinol Metab* 2005; **90**: 10-16 [PMID: 15483107 DOI: 10.1210/jc.2004-1330]

21 **Tatsuguchi A**, Miyake K, Gudis K, Futagami S, Tsukui T, Wada K, Kishida T, Fukuda Y, Sugisaki Y, Sakamoto C. Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. *Am J Gastroenterol* 2004; **99**: 2121-2127 [PMID: 15554990 DOI: 10.1111/j.1572-0241.2004.30291.x]

22 **Azuma T**, Suto H, Ito Y, Ohtani M, Dojo M, Kuriyama M, Kato T. Gastric leptin and Helicobacter pylori infection. *Gut* 2001; **49**: 324-329 [PMID: 11511551]

23 **Abenavoli L**, Milic N, Masarone M, Persico M. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. *Med Hypotheses* 2013; **81**: 913-915 [PMID: 24011768 DOI: 10.1016/j.mehy.2013.08.011]

24 **Upala S**, Sanguankeo A, Saleem SA, Jaruvongvanich V. Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2017; **29**: 153-159 [PMID: 27832037 DOI: 10.1097/MEG.0000000000000774]

25 **Salles N**, Ménard A, Georges A, Salzmann M, de Ledinghen V, de Mascarel A, Emeriau JP, Lamouliatte H, Mégraud F. Effects of Helicobacter pylori infection on gut appetite peptide (leptin, ghrelin) expression in elderly inpatients. *J Gerontol A Biol Sci Med Sci* 2006; **61**: 1144-1150 [PMID: 17167154]

**P-Reviewer:** Abenavoli L, Chmiela M, Tovey FI, Yamaoka Y, Vorobjova T

**S-Editor:** Gong ZM **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0



**Figure 1 The flow diagram of the subject selection in the study.**



**Figure 2 The scatter plots of change in value of body mass index along with body mass index at baseline in the *Helicobacter pylori* (+) and *Helicobacter pylori* (-) groups.** The trend lines were added in the two plots. A: *Helicobacter pylori* (*H. pylori*)(+) groups; B: *H. pylori* (-) group. BMI: body mass index.



**Figure 3 The scatter plots of change in body mass index value in the underweight, normal, overweight and obese subjects at baseline in the *Helicobacter pylori* (+) and *Helicobacter pylori* (-) groups.** The means were added in the two plots. A: *Helicobacter pylori* (*H. pylori*)(+) groups; B: *H. pylori* (-) group. BMI: body mass index.

**Table 1 The characteristics of subjects’ data at study baseline *n* (%)**

|  |  |  |
| --- | --- | --- |
| **Variable** | **Total (*n* = 3039)** | **Baseline data** |
| ***H. pylori* (+)** | ***H. pylori* (-)** | ***P* value** |
| Age (yr), mean ± SD | 49 ± 19 | 50 ± 19 | 47 ± 19 | < 0.001 |
| ≤ 45 | 1513 (49.8) | 737 (48.7) | 776 (51.3) | < 0.001 |
| 45-60 | 523 (17.2) | 319 (61.0) | 204 (39.0) |  |
| > 60 | 1003 (33.0) | 583 (58.1) | 420 (41.9) |  |
| Sex, female | 248 (8.2) | 137 (55.4) | 111 (44.6) | 0.662 |
| Marriage, single | 734 (24.2) | 358 (48.8) | 376 (51.2) | 0.001 |
| Underlying diseases | 770 (25.4) | 446 (57.9) | 324 (42.1) | 0.010 |
| Diabetes | 207 (6.8) | 121 (58.5) | 86 (41.6) | 0.175 |
| Hypertension | 642 (21.1) | 369 (57.5) | 273 (42.5) | 0.042 |
| Coronary heart disease | 177 (5.8) | 99 (55.9) | 78 (44.1) | 0.579 |
| LDL > 3.1 mmol/L | 816 (28.1) | 465 (57.0) | 351 (43.0) | 0.092 |
| HDL < 0.83 mmol/L | 823 (28.4) | 469 (57.0) | 354 (43.0) | 0.090 |
| TG > 1.71 mmol/L | 861 (28.3) | 488 (56.7) | 373 (43.3) | 0.056 |
| TC > 5.7 mmol/L | 614 (20.2) | 336 (54.7) | 278 (45.3) | 0.660 |
| FBG > 6.1 mmol/L | 439 (14.5) | 258 (58.8) | 181 (41.2) | 0.028 |
| BMI, kg/m2 | 24.5 ± 3.3 | 24.5 ± 3.2 | 24.4 ± 3.3 | 0.221 |
| Underweight | 62 (2.0) | 34 (54.8) | 28 (45.2) | 0.146 |
| Normal | 1342 (44.2) | 693 (51.6) | 649 (48.4) |  |
| Overweight | 1247 (41.0) | 700 (56.1) | 547 (43.9) |  |
| Obese | 388 (12.8) | 212 (54.6) | 176 (45.4) |  |

BMI: body mass index; LDL: low density lipoprotein; HDL: high density lipoprotein; FBG: fasting blood-glucose; TG: triglycerides; TC: total cholesterol; *H. pylori: Helicobacter pylori.*

**Table 2 The association between *Helicobacter pylori* and body mass index in the study**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **Change in BMI** | **Crude** | **Adjusted** |
| **Value** | ***P* value** | **RR (95%CI)** | ***P* value** | **RR (95%CI)** | ***P* value** |
| Model 1 in all the subjects |  |  |  |  |  |  |
| *H. pylori* (+) | -0.118 | < 0.001 | 0.963 (0.901-1.029) | 0.264 | 0.988 (0.924-1.057) | 0.729 |
| *H. pylori* (-) | -0.080 | < 0.001 | 1.000 |  | 1.000 |  |
| Model 2 in the subjects with obesity |  |  |  |  |  |  |
| *H. pylori* (+) | -0.431 | < 0.001 | 1.020 (0.791-1.317) | 0.876 | 1.038 (0.794-1.357) | 0.786 |
| *H. pylori* (-) | -0.411 | < 0.001 | 1.000 |  | 1.000 |  |
| Model 3 in the subjects with overweight |  |  |  |  |  |  |
| *H. pylori* (+) | -0.136 | < 0.001 | 0.942 (0.852-1.042) | 0.245 | 0.968 (0.874, 1.072) | 0.529 |
| *H. pylori* (-) | -0.196 | < 0.001 | 1.000 |  | 1.000 |  |
| Model 4 in the subjects with normal and underweight |  |  |  |  |  |  |
| *H. pylori* (+) | 0.0563 | 0.159 | 0.987 (0.908-1.074) | 0.764 | 1.009 (0.926-1.1) | 0.835 |
| *H. pylori* (-) | 0.0435 | 0.057 | 1.000 |  | 1.000 |  |

*H. pylori: Helicobacter pylori.*

**Table 3 The association between *Helicobacter pylori* and obesity in the study**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **Events** | **Crude** | **Adjusted** |
| **Base line** | **1 year** | **Incidence (%)** | **RR (95%CI)** | ***P* value** | **RR (95%CI)** | ***P* value** |
| Model 1 in all the subjects |  |  |  |  |  |  |  |
| *H. pylori* (+) | 212 (12.9) | 194 (11.8) | 18 (1.1) | 0.890 (0.626-1.267) | 0.519 | 0.831 (0.577-1.197) | 0.321 |
| *H. pylori* (-) | 176 (12.6) | 169 (12.1) | 7 (0.5) | 1.000 |  | 1.000 |  |
| Model 2 in the obese subjects |  |  |  |  |  |  |  |
| *H. pylori* (+) | 212 (100) | 170 (80.2) | 42 (19.8) | 0.995 (0.603-1.642) | 0.985 | 0.931 (0.547-1.585) | 0.792 |
| *H. pylori* (-) | 176 (100) | 141 (80.1) | 35 (19.1) | 1.000 |  | 1.000 |  |
| Model 3 in the non-obese subjects |  |  |  |  |  |  |  |
| *H. pylori* (+) | 0 | 24 (1.7) | 24 (1.7) | 0.731 (0.422-1.268) | 0.265 | 0.673 (0.382-1.186) | 0.170 |
| *H. pylori* (-) | 0 | 28 (2.3) | 28 (2.3) | 1.000 |  | 1.000 |  |

Note: The population was the same as in Table 2. *H. pylori: Helicobacter pylori.*